QNEGCONSET
QuicTPD™ Negative Control Set
packaging
pkg of 10 mg
Quality Level
sustainability
Greener Alternative Product
greener alternative category
storage temp.
2-8°C
Related Categories
General description
N-Methylated Pomalidomide is a ligand used as a negative control for pomalidomide in the recuitment of Cereblon (CRBN) protein, whereas (S,S,S) AHPC-hydrochloride is a ligand used as negative control for (S,R,S)-AHPC in the recruitment of von-Hippel Lindau (VHL) protein. N-methylation of pomalidomide or the inversion of stereochemistry to yield of (S,S,S) AHPC prevents binding to CRBN and VHL proteins. These are provided at 10mg each.
We are committed to bringing you Greener Alternative Products. This product is a Design for Sustainability (DfS) developed product, which belongs to one of the four categories of greener alternatives. Click here to view its DfS scorecard.
Application
Useful for construction of small molecules structurally similar to PROTACs of interest but with no inherent degradation action in themselves serving as negative control.
Features and Benefits
Structural similarity to active CRBN/VHL ligands is optimal for construction of negative controls. The amino terminus in each can be used for attaching bifunctional linkers with reactions such as peptide coupling.
Other Notes
Negative Control Set part of QuicTPD™ kit
Legal Information
QuicTPD is a trademark of Merck KGaA, Darmstadt, Germany
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Certificates of Analysis (COA)
Lot/Batch Number
It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.
If you need assistance, please contact Customer Support
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Andrew P Crew et al.
Journal of medicinal chemistry, 61(2), 583-598 (2017-07-12)
Proteolysis targeting chimeras (PROTACs) are bifunctional molecules that recruit an E3 ligase to a target protein to facilitate ubiquitination and subsequent degradation of that protein. While the field of targeted degraders is still relatively young, the potential for this modality
Christian Steinebach et al.
ACS chemical biology, 13(9), 2771-2782 (2018-08-18)
The immunomodulatory drugs (IMiDs) thalidomide, lenalidomide, and pomalidomide, all approved for the treatment of multiple myeloma, induce targeted ubiquitination and degradation of Ikaros (IKZF1) and Aiolos (IKZF3) via the cereblon (CRBN) E3 ubiquitin ligase. IMiD-based proteolysis-targeting chimeras (PROTACs) can efficiently
Articles
Discover QuicTPD™ Acid/Amine Screening Sets for rapid, high-throughput PROTAC® synthesis, streamlining targeted protein degradation research.
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service